Advertisement

Journal of Autism and Developmental Disorders

, Volume 36, Issue 8, pp 1053–1064 | Cite as

Oral Human Immunoglobulin for Children with Autism and Gastrointestinal Dysfunction: A Prospective, Open-Label Study

  • Cindy K. Schneider
  • Raun D. Melmed
  • Leon E. Barstow
  • F. Javier Enriquez
  • James Ranger-Moore
  • James A. Ostrem
Original Paper

Abstract

Immunoglobulin secretion onto mucosal surfaces is a major component of the mucosal immune system. We hypothesized that chronic gastrointestinal (GI) disturbances associated with autistic disorder (AD) may be due to an underlying deficiency in mucosal immunity, and that orally administered immunoglobulin would be effective in alleviating chronic GI dysfunction in these individuals. In this pilot study, twelve male subjects diagnosed with AD were evaluated using a GI severity index (GSI) while receiving daily dosing with encapsulated human immunoglobulin. Following eight weeks of treatment, 50% of the subjects met prespecified criteria for response in GI signs and symptoms and showed significant behavioral improvement as assessed by the Autism Behavior Checklist and parent and physician rated Clinical Global Impression of Improvement.

Keywords

Autism Autistic Disorder Immunoglobulin Gastrointestinal dysfunction Mucosal immunity 

Notes

Acknowledgments

The authors would like to thank the subjects and parents for their participation in the study, the Southwest Autism Research and Resource Center for making its facility available during the study, and Janet Kirwan, RN and Monica McCabe, RN, OCN for their skill and dedication in ensuring that the study was conducted in compliance with the study protocol and regulatory guidelines. Funding for the study was provided by Protein Therapeutics, Inc.

References

  1. Anthony, A., Bjarnason, I., Sigthorsson, G., Montgomery, S. M., Murch, S. H., & Thompson, M., et al. (2000). Faecal calprotectin levels correlate with acute inflammation in autistic enterocolitis. Gut, 46(Suppl II), A3.Google Scholar
  2. Arnold, L. E., Aman, M. G., Martin, A., Collier-Crespin, A., Vitiello, B., & Tierney, E., et al. (2000). Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders, 30(2), 99–111.PubMedCrossRefGoogle Scholar
  3. Ashwood, P., Anthony, A., Pellicer, A. A., Torrente, F., Walker-Smith, J. A., & Wakefield, A. J. (2003). Intestinal lymphocyte populations in children with regressive autism: Evidence for extensive mucosal immunopathology. Journal of Clinical Immunology, 23(6), 504–517.PubMedCrossRefGoogle Scholar
  4. Barnes, G. L., Doyle, L. W., Hewson, P. H., Knoches, A. M., McLellan, J. A., & Kitchen, W. H., et al. (1982). A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet, 1(8286), 1371–1373.PubMedCrossRefGoogle Scholar
  5. Casswall, T. H., Hammarstrom, L., Veress, B., Nord, C. E., Bogstedt, A., & Brockstedt U., et al. (1996). Oral IgA–IgG treatment of chronic non-specific diarrhoea in infants and children. Acta Paediatrica, 85(9), 1126–1128.PubMedGoogle Scholar
  6. Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., McCarthy, K. S., & Ovrutskaya, I., et al. (2000). Secretin and autism: A two-part clinical investigation. Journal of Autism and Developmental Disorders, 30(2), 87–94.PubMedCrossRefGoogle Scholar
  7. Comi, A. M., Zimmerman, A. W., Frye, V. H., Law, P. A., & Peeden, J. N. (1999). Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. Journal of Child Neurology, 14(6), 388–394.PubMedGoogle Scholar
  8. Connolly, A. M., Chez, M. G., Pestronk, A., Arnold, S. T., Mehta, S., Deuel, R. K. (1999). Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. Journal of Pediatrics, 134(5), 607–613.PubMedCrossRefGoogle Scholar
  9. Dalakas, M. C. (1997). Intravenous immune globulin therapy for neurologic diseases. Annals of Internal Medicine, 126(9), 721–730.PubMedGoogle Scholar
  10. Daniels, W. W., Warren, R. P., Odell, J. D., Maciulis, A., Burger, R. A., & Warren, W. L., et al. (1995). Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology, 32(3), 120–123.PubMedCrossRefGoogle Scholar
  11. Eibl, M. M., Wolf, H. M., Furnkranz, H., & Rosenkranz, A. (1988). Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA–IgG feeding. New England Journal of Medicine, 319(1), 1–7.PubMedCrossRefGoogle Scholar
  12. Furlano, R. I., Anthony, A., Day, R., Brown, A., McGarvey, L., & Thomson, M. A., et al. (2001). Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. Journal of Pediatrics, 138(3), 366–372.PubMedCrossRefGoogle Scholar
  13. Harvey, R. F., & Bradshaw, J. M. (1980). A simple index of Crohn’s-disease activity. Lancet, 1(8167), 514.PubMedCrossRefGoogle Scholar
  14. Horvath, K., Papadimitriou, J. C., Rabsztyn, A., Drachenberg, C., & Tildon, J. T. (1999). Gastrointestinal abnormalities in children with autistic disorder. Journal of Pediatrics, 135(5), 559–563.PubMedCrossRefGoogle Scholar
  15. Horvath, K., & Perman, J. A. (2002). Autism and gastrointestinal symptoms. Current Gastroenterology Reports, 4(3), 251–258.PubMedGoogle Scholar
  16. Hyams, J. S., Mandel, F., Ferry, G. D., Gryboski, J. D., Kibort, P. M., Kirschner B. S., et al. (1992). Relationship of common laboratory parameters to the activity of Crohn’s disease in children. Journal of Pediatric Gastroenterology and Nutrition, 14(2), 216–222.PubMedCrossRefGoogle Scholar
  17. Jyonouchi, H., Sun, S., & Le, H. (2001). Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. Journal of Neuroimmunology, 120(1–2), 170–179.PubMedCrossRefGoogle Scholar
  18. Kanfer, E. J., Abrahamson, G., Taylor, J., Coleman, J. C., & Samson, D. M. (1994). Severe rotavirus-associated diarrhoea following bone marrow transplantation: treatment with oral immunoglobulin. Bone Marrow Transplantation, 14(4), 651–652.PubMedGoogle Scholar
  19. Kazatchkine, M. D., & Kaveri, S. V. (2001). Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine, 345(10), 747–755.PubMedCrossRefGoogle Scholar
  20. Korvatska, E., Van de Water, J., Anders, T. F., Gershwin, M. E. (2002). Genetic and immunologic considerations in autism. Neurobiology of Disease, 9(2), 107–125.PubMedCrossRefGoogle Scholar
  21. Krug, D. A., Arick, J., & Almond, P. (1980). Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. Journal of Child Psychology and Psychiatry, 21(3), 221–229.PubMedCrossRefGoogle Scholar
  22. Krug, D. A., Arick, J., & Almond, P. (1993). Autism screening instrument for educational planning. Examiner’s manual (1st ed.). Austin, Texas: Pro-ed.Google Scholar
  23. Kuddo, T., Nelson, K. B. (2003). How common are gastrointestinal disorders in children with autism?. Current Opinion in Pediatrics, 15(3), 339–343.PubMedCrossRefGoogle Scholar
  24. Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., & Galler, G., et al. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New England Journal of Medicine, 330(26), 1841–1845.PubMedCrossRefGoogle Scholar
  25. Melamed, I., Griffiths, A. M., & Roifman, C. M. (1991). Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea. Journal of Pediatrics, 119(3), 486–489.PubMedCrossRefGoogle Scholar
  26. Melmed, R. D., Schneider, C. K., Fabes, R. A., Phillips, J., & Reichelt, K. (2000). Metabolic markers and gastrointestinal symptoms in children with autism and related disorders. Journal of Pediatric Gastroenterology and Nutrition, 31(Suppl 2), A116.Google Scholar
  27. Messahel, S., Pheasant, A. E., Pall, H., Ahmed-Choudhury, J., Sungum-Paliwal, R. S., & Vostanis, P. (1998). Urinary levels of neopterin and biopterin in autism. Neuroscience Letters, 241(1), 17–20.PubMedCrossRefGoogle Scholar
  28. Molloy, C. A., & Manning-Courtney, P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism, 7(2), 165–171.PubMedCrossRefGoogle Scholar
  29. Money, J., Bobrow, N. A., & Clarke, F. C. (1971). Autism and autoimmune disease: a family study. Journal of Autism and Childhood Schizophrenia, 1(2), 146–160.PubMedCrossRefGoogle Scholar
  30. Myren, J., Bouchier, I. A., Watkinson, G., Softley, A., Clamp, S. E., & de Dombal, F. T. (1984). The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976–1982. A further report on 2,657 cases. Scandinavian Journal of Gastroenterology. Supplement, 95, 1–27.PubMedGoogle Scholar
  31. NIMH, (1985). CGI (Clinical Global Impression) scale. Psychopharmacology Bulletin, 21, 839–840.Google Scholar
  32. Piven, J. (1997). The biological basis of autism. Current Opinion in Neurobiology, 7(5), 708–712.PubMedCrossRefGoogle Scholar
  33. Roberts, W., Weaver, L., Brian, J., Bryson, S., Emelianova, S., & Griffiths, A. M., et al. (2001). Repeated doses of porcine secretin in the treatment of autism: A randomized, placebo-controlled trial. Pediatrics, 107(5), E71.PubMedCrossRefGoogle Scholar
  34. Schott, J. M., Harkness, K., Barnes, J., della Rocchetta, A. I., Vincent, A., & Rossor, M. N. (2003). Amnesia, cerebral atrophy, and autoimmunity. Lancet, 361(9365), 1266.PubMedCrossRefGoogle Scholar
  35. Singh, V. K. (1996). Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. Journal of Neuroimmunology, 66(1–2), 143–145.PubMedCrossRefGoogle Scholar
  36. Singh, V. K., Warren, R., Averett, R., & Ghaziuddin, M. (1997). Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatric Neurology, 17(1), 88–90.PubMedCrossRefGoogle Scholar
  37. Sweeten, T. L., Bowyer, S. L., Posey, D. J., Halberstadt, G. M., & McDougle, C. J. (2003). Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics, 112(5), e420.PubMedCrossRefGoogle Scholar
  38. Sweeten, T. L., Posey, D. J., & McDougle, C. J. (2003). High blood monocyte counts and neopterin levels in children with autistic disorder. American Journal of Psychiatry, 160(9), 1691–1693.PubMedCrossRefGoogle Scholar
  39. Szatmari, P., Jones, M. B., Zwaigenbaum, L., MacLean, J. E. (1998). Genetics of autism: Overview and new directions. Journal of Autism and Developmental Disorders, 28(5), 351–368.PubMedCrossRefGoogle Scholar
  40. Takai, T. (2002). Roles of Fc receptors in autoimmunity. Nature Reviews Immunology, 2(8), 580–592.PubMedGoogle Scholar
  41. Torrente, F., Anthony, A., Heuschkel, R. B., Thomson, M. A., Ashwood, P., & Murch, S. H. (2004). Focal-enhanced gastritis in regressive autism with features distinct from Crohn’s and Helicobacter pylori gastritis. American Journal of Gastroenterology, 99(4), 598–605.PubMedCrossRefGoogle Scholar
  42. Torrente, F., Ashwood, P., Day, R., Machado, N., Furlano, R. I., & Anthony, A., et al. (2002). Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Molecular Psychiatry, 7(4), 375–382.PubMedCrossRefGoogle Scholar
  43. Torres, A.R., Maciulis, A., & Odell, D. (2001). The association of MHC genes with autism. Frontiers in Bioscience, 6, D936–D943.PubMedGoogle Scholar
  44. Vincent, A., Lily, O., & Palace, J. (1999). Pathogenic autoantibodies to neuronal proteins in neurological disorders. Journal of Neuroimmunology, 100(1–2), 169–180.PubMedCrossRefGoogle Scholar
  45. Wakefield, A. J., Anthony, A., Murch, S. H., Thomson, M., & Montgomery, S. M., Davies, S., et al. (2000). Enterocolitis in children with developmental disorders. American Journal of Gastroenterology, 95(9), 2285–2295.PubMedCrossRefGoogle Scholar
  46. Warny, M., Fatimi, A., Bostwick, E. F., Laine, D. C., Lebel, F., & LaMont, J. T., et al. (1999). Bovine immunoglobulin concentrate—Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut, 44(2), 212–217.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Cindy K. Schneider
    • 1
    • 2
  • Raun D. Melmed
    • 1
  • Leon E. Barstow
    • 3
  • F. Javier Enriquez
    • 3
    • 5
  • James Ranger-Moore
    • 6
  • James A. Ostrem
    • 3
    • 4
  1. 1.Southwest Autism Research and Resource CenterPhoenixUSA
  2. 2.Center for Autism Research & EducationPhoenixUSA
  3. 3.Protein Therapeutics, Inc.,TucsonUSA
  4. 4.ImaRx Therapeutics, Inc.,TucsonUSA
  5. 5.UCB Clinical DevelopmentSmyrnaUSA
  6. 6.Cancer Center Biometry Unit, University of Arizona Health Sciences CenterUniversity of ArizonaTucsonUSA

Personalised recommendations